Skip to main content
PMC home page
Infection and Immunity logoLink to Infection and Immunity
. 1985 Aug;49(2):281–285. doi: 10.1128/iai.49.2.281-285.1985

Opsonophagocytic killing activity of rabbit antibody to Pseudomonas aeruginosa mucoid exopolysaccharide.

P Ames, D DesJardins, G B Pier
PMCID: PMC262011  PMID: 3160660

Abstract

We used an in vitro opsonophagocytic killing assay to measure the functional activity of antibody directed at the mucoid exopolysaccharide (MEP) antigen expressed by Pseudomonas aeruginosa strains isolated from cystic fibrosis patients. Rabbit antibodies raised to purified MEP were able to mediate phagocytic killing in the presence of human peripheral blood leukocytes and a low level (final concentration, 0.3%) of fresh normal human serum as a complement source. No bacterial killing was observed when peripheral blood leukocytes, antiserum, or complement was omitted. Specificity of the antibody for the MEP antigen was shown by adsorption and inhibition assays. Affinity-purified antibody to MEP also mediate phagocytic killing. These data indicate that antiphagocytic properties attributable to MEP can be overcome by specific antibody.

Full text

PDF
281

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bryan L. E., Kureishi A., Rabin H. R. Detection of antibodies to Pseudomonas aeruginosa alginate extracellular polysaccharide in animals and cystic fibrosis patients by enzyme-linked immunosorbent assay. J Clin Microbiol. 1983 Aug;18(2):276–282. doi: 10.1128/jcm.18.2.276-282.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Carlson D. M., Matthews L. W. Polyuronic acids produced by Pseudomonas aeruginosa. Biochemistry. 1966 Sep;5(9):2817–2822. doi: 10.1021/bi00873a006. [DOI] [PubMed] [Google Scholar]
  3. Fick R. B., Jr, Naegel G. P., Matthay R. A., Reynolds H. Y. Cystic fibrosis pseudomonas opsonins. Inhibitory nature in an in vitro phagocytic assay. J Clin Invest. 1981 Oct;68(4):899–914. doi: 10.1172/JCI110345. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Fick R. B., Jr, Naegel G. P., Squier S. U., Wood R. E., Gee J. B., Reynolds H. Y. Proteins of the cystic fibrosis respiratory tract. Fragmented immunoglobulin G opsonic antibody causing defective opsonophagocytosis. J Clin Invest. 1984 Jul;74(1):236–248. doi: 10.1172/JCI111407. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Hancock R. E., Mutharia L. M., Chan L., Darveau R. P., Speert D. P., Pier G. B. Pseudomonas aeruginosa isolates from patients with cystic fibrosis: a class of serum-sensitive, nontypable strains deficient in lipopolysaccharide O side chains. Infect Immun. 1983 Oct;42(1):170–177. doi: 10.1128/iai.42.1.170-177.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Peterson P. K., Kim Y., Schmeling D., Lindemann M., Verhoef J., Quie P. G. Complement-mediated phagocytosis of Pseudomonas aeruginosa. J Lab Clin Med. 1978 Dec;92(6):883–894. [PubMed] [Google Scholar]
  7. Pier G. B., Ames P. Mediation of the killing of rough, mucoid isolates of Pseudomonas aeruginosa from patients with cystic fibrosis by the alternative pathway of complement. J Infect Dis. 1984 Aug;150(2):223–228. doi: 10.1093/infdis/150.2.223. [DOI] [PubMed] [Google Scholar]
  8. Pier G. B., Elcock M. E. Nonspecific immunoglobulin synthesis and elevated IgG levels in rabbits immunized with mucoid exopolysaccharide from cystic fibrosis isolates of Pseudomonas aeruginosa. J Immunol. 1984 Aug;133(2):734–739. [PubMed] [Google Scholar]
  9. Pier G. B., Matthews W. J., Jr, Eardley D. D. Immunochemical characterization of the mucoid exopolysaccharide of Pseudomonas aeruginosa. J Infect Dis. 1983 Mar;147(3):494–503. doi: 10.1093/infdis/147.3.494. [DOI] [PubMed] [Google Scholar]
  10. Pier G. B. Safety and immunogenicity of high molecular weight polysaccharide vaccine from immunotype 1 Pseudomonas aeruginosa. J Clin Invest. 1982 Feb;69(2):303–308. doi: 10.1172/JCI110453. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Pier G. B., Thomas D. M. Characterization of the human immune response to a polysaccharide vaccine from Pseudomonas aeruginosa. J Infect Dis. 1983 Aug;148(2):206–213. doi: 10.1093/infdis/148.2.206. [DOI] [PubMed] [Google Scholar]
  12. Schwarzmann S., Boring J. R. Antiphagocytic Effect of Slime from a Mucoid Strain of Pseudomonas aeruginosa. Infect Immun. 1971 Jun;3(6):762–767. doi: 10.1128/iai.3.6.762-767.1971. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Speert D. P., Lawton D., Mutharia L. M. Antibody to Pseudomonas aeruginosa mucoid exopolysaccharide and to sodium alginate in cystic fibrosis serum. Pediatr Res. 1984 May;18(5):431–433. doi: 10.1203/00006450-198405000-00008. [DOI] [PubMed] [Google Scholar]
  14. Verhoef J., Peterson P. K., Quie P. G. Kinetics of staphylococcal opsonization, attachment, ingestion and killing by human polymorphonuclear leukocytes: a quantitative assay using [3H]thymidine labeled bacteria. J Immunol Methods. 1977;14(3-4):303–311. doi: 10.1016/0022-1759(77)90141-7. [DOI] [PubMed] [Google Scholar]
  15. Young L. S., Armstrong D. Human immunity to Pseudomonas aeruginosa. I. In-vitro interaction of bacteria, polymorphonuclear leukocytes, and serum factors. J Infect Dis. 1972 Sep;126(3):257–276. doi: 10.1093/infdis/126.3.257. [DOI] [PubMed] [Google Scholar]
  16. di Sant'agnese P. A., Davis P. B. Cystic fibrosis in adults. 75 cases and a review of 232 cases in the literature. Am J Med. 1979 Jan;66(1):121–132. doi: 10.1016/0002-9343(79)90491-1. [DOI] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES